Stockreport

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer [Yahoo! Finance]

Agenus Inc.  (AGEN) 
Last agenus inc. earnings: 3/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: agenusbio.com/investors
PDF combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) [Read more]